Clinical Research Technology S.r.l.
Clinical Research Technology S.r.l.
Explore linked clinical trials.8 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not stated | 2026-09-14 | NCT04660435 | |
| Adjuvant Treatment in Premenopausal Breast Cancer | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Recruiting | Not stated | 2026-09-03 | NCT06807749 | |
| Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Active, not recruiting | Phase 2 | 2026-06-18 | NCT04722575 | |
| Evaluation of the Safety and Performance of the Medical Device RDM36 in the Treatment of Periodontal Gingival Contraction and in Black Triangles Syndrome (BTS) | Black Triangles Syndrome (BTS); Periodontal Gingival Contraction | Recruiting | Not applicable | 2026-05-12 | NCT07185191 | |
| CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-05-06 | NCT02918084 | |
| PREgnancy and FERtility Registry | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not stated | 2026-04-30 | NCT02895165 | |
| National Register of Actionable Mutations | Solid Tumours in Advanced Stages | Active, not recruiting | Not stated | 2026-01-30 | NCT05918666 | |
| Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19. | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma, squamous cell neoplasm | Recruiting | Phase 2 | 2025-03-14 | NCT06869473 |